Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

Rhea-AI Summary

Seer (Nasdaq: SEER) said the U.S. Patent and Trademark Office Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360, which protect its Proteograph nanoparticle protein enrichment methods.

The ’360 patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer; the decision affirms key claim coverage of Proteograph’s nano- and microparticle protein-corona technology.

Seer noted the platform is supported by an IP portfolio of more than 240 issued and pending patents, including 80 issued patents.

Positive

• 23 patent claims upheld by PTAB on March 23, 2026
• Exclusive license to Brigham and Women’s Hospital protects Proteograph methods
• IP portfolio >240 issued and pending patents, including 80 issued

Negative

• 6 claims not upheld out of 29 total claims (29 total minus 23 upheld)
• Inter partes review was filed by Bruker subsidiaries, signaling prior challenger interest

News Market Reaction – SEER

+1.20%

+1.20% Session close to close

In the Mar 30 session, SEER gained 1.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms that 23 claims of U.S. Patent No. 11,435,360, including 5 challenged clai...

Analysis

This announcement confirms that 23 claims of U.S. Patent No. 11,435,360, including 5 challenged claims, remain valid, reinforcing IP around Seer’s nanoparticle-based Proteograph platform. The decision directly supports its deep proteomic analysis capabilities. In context of recent activist campaigns, tax benefit preservation measures, and continued operating losses, investors may watch how this patent strength translates into commercial adoption, revenue growth, and any shifts in governance or capital allocation strategy.

Key Figures

Valid patent claims: 23 claims Challenged claims: 11 claims Total patent claims: 29 claims +4 more

7 metrics

Valid patent claims 23 claims U.S. Patent No. 11,435,360 remain valid after PTAB review

Challenged claims 11 claims Number of ’360 Patent claims challenged in inter partes review

Total patent claims 29 claims Total claims in U.S. Patent No. 11,435,360 B2

Upheld challenged claims 5 claims Challenged claims that remain valid and protect Seer’s technology

Unchallenged claims 18 claims Unchallenged ’360 Patent claims that remain valid

IP portfolio size more than 240 Issued patents and pending applications worldwide supporting Proteograph suite

Issued patents 80 issued patents Part of Seer’s broader intellectual property portfolio

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 04	Activist letter	Positive	+2.8%	Radoff-JEC Group open letter to independent directors seeking changes.
Feb 26	Tax plan adoption	Negative	-17.3%	Adoption of tax benefit preservation plan and rights dividend to protect NOLs.
Feb 26	Earnings and outlook	Negative	-17.3%	Report of 2025 results with losses and cautious 2026 revenue outlook.
Feb 23	Activist campaign	Positive	+4.0%	Activist letter citing performance, cash use, and compensation concerns.
Feb 19	Scientific showcase	Positive	+2.5%	US HUPO 2026 presentations highlighting Proteograph-enabled proteomics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Governance and activist headlines have recently produced modest gains, while earnings and tax preservation plan news coincided with sharper declines around -17%, suggesting sensitivity to balance-sheet and governance structures.

Recent Company History

Over the past weeks, Seer has faced intense governance focus, with activist investors (Radoff-JEC Group) pressing for change on Feb 19 and Feb 23, both followed by single-day gains of about 2–4%. In contrast, its Feb 26 earnings release and adoption of a tax benefit preservation plan each saw roughly -17% reactions. Product visibility events, such as US HUPO 2026 on Feb 19, drew smaller positive moves. Today’s patent decision reinforces the Proteograph platform’s IP base against this backdrop of activist pressure and mixed fundamental sentiment.

Key Terms

patent trial and appeal board, inter partes review, engineered nano- and microparticles, protein coronas, +4 more

8 terms

patent trial and appeal board regulatory

"the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office"

The Patent Trial and Appeal Board is an administrative body that reviews and decides challenges to the validity of issued patents and hears appeals of patent office decisions. For investors, its rulings can make or break a company’s exclusive rights to a product or technology—similar to a referee overturning a game-winning call—affecting future revenue, legal costs, and the value of related securities.

inter partes review regulatory

"issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S."

An inter partes review is a formal proceeding at the U.S. Patent Office where a third party asks a panel to re-examine and possibly cancel all or part of an issued patent based on earlier public information. Investors care because the outcome can remove or uphold a company’s exclusive rights, directly affecting product exclusivity, potential revenue, legal exposure and the valuation of businesses that rely on that patent—like asking a neutral referee to re-check a key call in a game.

engineered nano- and microparticles medical

"covers methods for analyzing biological samples using engineered nano- and microparticles"

Engineered nano- and microparticles are tiny, purpose-built bits of material—ranging from a thousandth to a billionth of a meter—designed to carry, protect or change how a substance behaves, much like microscopic delivery trucks or building blocks. They matter to investors because they can enable new drugs, diagnostics, coatings or devices, creating commercial opportunities but also bringing manufacturing challenges, regulatory scrutiny and safety risks that affect value and timelines.

protein coronas medical

"engineered nano- and microparticles that form protein coronas, resulting in protein enrichment"

Protein coronas are layers of blood or tissue proteins that stick to the surface of tiny drug carriers or diagnostic particles when they enter the body, effectively giving the particle a new biological “coat.” This coat can change how the particle is seen by the immune system, where it travels, how long it lasts, and whether it works as intended, so investors watch protein coronas because they affect a product’s safety, effectiveness, and regulatory approval risk.

proteomic analysis medical

"underlies Seer’s Proteograph platform for deep proteomic analysis."

Proteomic analysis is the study and measurement of all the proteins a cell, tissue or organism makes, using laboratory tools to identify which proteins are present, how much of each exists and how they change under different conditions. For investors, it matters because these results help drug developers find disease targets, validate therapies or show whether a treatment is working—similar to reading a car’s dashboard to diagnose problems and predict future performance, which can influence a company’s prospects and value.

biofluids medical

"technology for analyzing biological samples, including cells, tissues and biofluids."

Biofluids are the liquids naturally produced by living organisms—such as blood, urine, saliva, sweat and spinal fluid—that carry cells, chemicals and other biological signals. For investors, they matter because those signals are the raw material for diagnostics, monitoring and drug testing: companies that can reliably read or use biofluids can create medical tests, monitoring devices or therapies that drive sales, regulatory decisions and adoption in healthcare markets.

proteomics medical

"leader in deep, unbiased proteomic insights, today announced that the Patent"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

nanoparticles medical

"integrates proprietary engineered nanoparticles, automation instrumentation, and analytical software"

Extremely tiny bits of matter, measured in billionths of a meter, that can behave differently from the same material at larger sizes. Think of them as microscopic delivery trucks or building blocks that can carry drugs to specific cells, boost material strength, or enable new electronic features. Investors care because nanoparticle use can change a product’s effectiveness, manufacturing complexity, regulatory scrutiny, patent value and cost profile, all of which affect a company’s future revenue and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the ’360 Patent.

The ’360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that underlies Seer’s Proteograph platform for deep proteomic analysis. The ’360 Patent is owned by The Brigham and Women’s Hospital, Inc. and is exclusively licensed to Seer.

A total of 23 claims, including five challenged claims and 18 unchallenged claims, remain valid and protect Seer’s nanoparticle protein enrichment technology for analyzing biological samples, including cells, tissues and biofluids. The upheld claims are directed to detecting proteins across a wide concentration range and to particle-related aspects of Seer’s technology, both of which enable deep proteomic analysis.

“The PTAB’s decision affirms the strength of our technology and our Proteograph platform,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Seer pioneered the Proteograph platform, and our approach enables the deep, reproducible, and scalable proteomics data our customers depend on. We will continue to defend and invest in the IP that protects our technology and makes it possible for us to continue bringing exceptional insights to our customers.”

Seer’s Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, and analytical software to enable deep, unbiased proteomics at scale. The platform is supported by an intellectual property portfolio of more than 240 issued patents and pending patent applications worldwide, including 80 issued patents.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite integrates proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and advanced analytical software. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the strength and scope of Seer's intellectual property portfolio, Seer's ability to protect its innovations and market position, and the company's plans to pursue available legal options. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych or Connor O’Neill
investor@seer.bio 

FAQ

What did Seer (SEER) announce about its ’360 patent on March 30, 2026?

Seer said PTAB issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360. According to the company, those claims protect Proteograph’s engineered nano- and microparticle protein-enrichment methods used for deep proteomic analysis.

How many claims of U.S. Patent No. 11,435,360 did PTAB uphold in the SEER decision?

The PTAB upheld 23 claims of U.S. Patent No. 11,435,360. According to the company, this includes five challenged claims and 18 previously unchallenged claims that support Proteograph technology.

Who challenged Seer’s ’360 patent and what was the outcome for SEER?

PreOmics GmbH and Biognosys AG, Bruker subsidiaries, filed the inter partes review; PTAB upheld 23 claims. According to the company, the decision affirms core Proteograph nanoparticle claim coverage.

Does Seer hold the ’360 patent directly, and what is the licensing status for SEER?

The ’360 patent is owned by Brigham and Women’s Hospital and is exclusively licensed to Seer. According to the company, the exclusive license secures Proteograph use of the patented methods.

What part of Proteograph technology is covered by the upheld SEER patent claims?

The upheld claims cover particle-related aspects and detection of proteins across wide concentration ranges. According to the company, these claims enable deep, reproducible proteomic analysis using Proteograph.

How large is Seer’s intellectual property portfolio as noted in the announcement?

Seer reported an IP portfolio of more than 240 issued and pending patents, including 80 issued patents. According to the company, this portfolio supports the Proteograph Product Suite and related technologies.